Patents by Inventor Ton That Hai

Ton That Hai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080021381
    Abstract: A medical device, such as a vascular access device, is disclosed for providing access to a medical fluid flow path for the introduction or withdrawal of medical fluids to and from the flow path. The access device includes an indicator for providing a visual indication when the access device has been exposed to an antiseptic agent.
    Type: Application
    Filed: July 20, 2007
    Publication date: January 24, 2008
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Kent L. LURVEY, Shmuel STERNBERG, Vadim V. KRONGAUZ, Rosa H. YEH, Robin G. PAULEY, Dustin C. CAWTHON, Ton That HAI, Lecon L. WOO, Ashok K. KHANNA, Birendra K. LAL, Michael Tung-Kiung LING, William S. HOERLE, Craig L. SANDFORD, Mark A. NORDHAUS, Alexander SAVITSKI, Nicklaus J. KIRICHKOW, Kenneth Glen SUH, Sivaramakrishnan KRISHNAMOORTHY, Hsinjin E. YANG, Robert A. CLARKE
  • Patent number: 7241272
    Abstract: Methods and devices for providing dialysis treatment are provided. The device includes a resin bed including zirconium phosphate, zirconium oxide, and urease.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: July 10, 2007
    Assignee: Baxter International Inc.
    Inventors: Sujatha Karoor, Brian Donovan, Ton That Hai, Mari Katada, Luis Lu, Leo Martis, Stavroula Morti, Salim Mujais, Paul J. Sanders, Paul J. Soltys, Rahul Tandon
  • Patent number: 7211560
    Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.
    Type: Grant
    Filed: December 29, 2003
    Date of Patent: May 1, 2007
    Assignees: Baxter International, Inc., Baxter Healthcare S.A.
    Inventors: Douglas L. Looker, Izydor Z. Apostol, Eric A. Brucker, Michael P. Doyle, David L. Foster, Christopher B. Glascock, James C. Hartman, Geoffrey F. Lee, Douglas D. Lemon, Edwin G. Moore, Jane P. Richards, Michael R. Schick, Stephen P. Trimble, David Pereira, Ton-That Hai, Kenneth E. Burhop
  • Patent number: 7135156
    Abstract: Methods of producing zirconium oxide compositions and using same are provided. The zirconium oxide compositions in crystalline form can be prepared by a synthetic process wherein the hydrolysis of zirconyl chloride and particle formation can be achieved simultaneously. Alternatively, the particle formation can occur first and then followed by hydrolysis with a base solution. The processes utilize a zirconyl salt solution that includes a zirconyl salt in isopropanol and water.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: November 14, 2006
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Ton That Hai, Mark Nordhaus, Paul Sanders, Cong Jiang, Sujatha Karoor
  • Publication number: 20040259769
    Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.
    Type: Application
    Filed: December 29, 2003
    Publication date: December 23, 2004
    Applicants: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Douglas L. Looker, Izydor Z. Apostol, Eric A. Brucker, Michael P. Doyle, David L. Foster, Christopher B. Glascock, James C. Hartman, Geoffrey F. Lee, Douglas D. Lemon, Edwin G. Moore, Jane P. Richards, Michael R. Schick, Stephen P. Trimble, David Pereira, Ton-That Hai, Kenneth E. Burhop
  • Publication number: 20040191162
    Abstract: Methods of producing zirconium oxide compositions and using same are provided. The zirconium oxide compositions in crystalline form can be prepared by a synthetic process wherein the hydrolysis of zirconyl chloride and particle formation can be achieved simultaneously. Alternatively, the particle formation can occur first and then followed by hydrolysis with a base solution. The processes utilize a zirconyl salt solution that includes a zirconyl salt in isopropanol and water.
    Type: Application
    Filed: March 28, 2003
    Publication date: September 30, 2004
    Inventors: Ton That Hai, Mark Nordhaus, Paul Sanders, Cong Jiang, Sujatha Karoor
  • Patent number: 6670323
    Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.
    Type: Grant
    Filed: November 10, 2000
    Date of Patent: December 30, 2003
    Assignees: Baxter International, Inc., Baxter Healthcare S.A.
    Inventors: Douglas L. Looker, Izydor Z. Apostol, Eric A. Brucker, Michael P. Doyle, David L. Foster, Christopher B. Glascock, James C. Hartman, Geoffrey F. Lee, Douglas D. Lemon, Edwin G. Moore, Jane P. Richards, Michael R. Schick, Stephen P. Trimble, David Pereira, Ton-That Hai, Kenneth E. Burhop
  • Publication number: 20030149307
    Abstract: A two step process for the preparation of polyethylene glycol-bis amine comprising a first step of reacting the terminal hydroxy groups of polyethylene glycol with a halogen substituted aromatic sulfonyl halide in a solvent to form a disubstituted sulfonyl activated polyethylene glycol intermediate. In a second step the intermediate is directly aminated with ammonia to give polyethylene glycol-bis amine.
    Type: Application
    Filed: October 15, 2002
    Publication date: August 7, 2003
    Applicant: Baxter International Inc.
    Inventors: Ton That Hai, Larry J. Markoski, David E. Pereira, Mark Nordhaus
  • Publication number: 20030105424
    Abstract: Methods and devices for providing dialysis treatment are provided. The device includes a resin bed including zirconium phosphate, zirconium oxide, and urease.
    Type: Application
    Filed: November 13, 2001
    Publication date: June 5, 2003
    Inventors: Sujatha Karoor, Brian Donovan, Ton That Hai, Mari Katada, Luis Lu, Leo Martis, Stavroula Morti, Salim Mujais, Paul J. Sanders, Paul J. Soltys, Rahul Tandon
  • Publication number: 20030103888
    Abstract: Compositions including zirconium phosphate particles as well as methods of synthesizing and using same are provided. The zirconium phosphate particles are synthesized through the use of polyphosphate and zirconyl chloride.
    Type: Application
    Filed: November 13, 2001
    Publication date: June 5, 2003
    Inventors: Ton That Hai, Paul Sanders, Mark Nordhaus, Sujatha Karoor, Cong Jiang, Ben Melnick
  • Patent number: 6204254
    Abstract: A novel group of compounds is disclosed for decorating the surface of synthetic polymeric or tissue derived prostheses to prevent adverse rejection events. The decorating molecules are obtained as derivatives of naturally occurring polysaccharides, derivatized to provide functionally reactive groups at the termini thereof, and the reacting with nucleophilic or other groups on the surface of the prosthesis in a simple one step reaction. Some of these reagents are useful in noncovalent adsorption to polyolefinic or perfluorocarbon based materials. Finally, phospholipids partially substituted with the nonantigenic polysaccharides provide a superior bipolar component for liposome formation.
    Type: Grant
    Filed: September 12, 1997
    Date of Patent: March 20, 2001
    Assignee: Baxter International, Inc.
    Inventors: Deanna J. Nelson, Ton That Hai, David E. Pereira, Timothy N. Estep
  • Patent number: 6018035
    Abstract: Novel polysaccharide compounds are disclosed for decorating biomolecular surfaces to increase isotropic size and mask antigenicity. The oligosaccharides may be synthesized as repeating disaccharide units, or may be derived by acid hydrolysis of naturally occurring polysaccharides. Such natural sources include chondroitins obtained from shark cartilage, or hyaluronic acid. The polyanionic sulfate groups contained in the sugar moieties impart negative charges which repel the molecules from the negatively charged wall of capillaries, to lengthen retention times of decorated drug molecules, such as crosslinked hemoglobin, in the peripheral circulation.
    Type: Grant
    Filed: July 21, 1997
    Date of Patent: January 25, 2000
    Assignee: Baxter International Inc.
    Inventors: Ton That Hai, David E. Pereira, Deanna J. Nelson
  • Patent number: 5981710
    Abstract: Novel polysaccharide compounds are disclosed for decorating biomolecular surfaces to increase isotropic size and mask antigenicity. The oligosaccharides may be synthesized as repeating disaccharide units, or may be derived by acid hydrolysis of naturally occurring polysaccharides. Such natural sources include chondroitins obtained from shark cartilage, or hyaluronic acid. The polyanionic sulfate groups contained in the sugar moieties impart negative charges which repel the molecules from the negatively charged wall of capillaries, to lengthen retention times of decorated drug molecules, such as crosslinked hemoglobin, in the peripheral circulation.
    Type: Grant
    Filed: July 21, 1997
    Date of Patent: November 9, 1999
    Assignee: Baxter International, Inc.
    Inventors: Ton That Hai, David E. Pereira, Deanna J. Nelson